Results 71 to 80 of about 2,979 (199)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies

Neuropsychiatric Disease and Treatment, 2021
Ágota Barabássy,1 Barbara Sebe,1 Károly Acsai,1 István Laszlovszky,1 Balázs Szatmári,1 Willie R Earley,2 György Németh1 1Medical Division, Gedeon Richter Plc, Budapest, Hungary; 2Clinical Development,
Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G   +6 more
doaj  

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 412-419, August 2026.
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park, Yitian Zhou, Volker M. Lauschke   +2 more
wiley   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 345-356, August 2026.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Beyond the Outburst: Charting a New Frontier for Understanding and Treating Irritability in Autistic Adults

Autism Research, Volume 19, Issue 7, July 2026.
ABSTRACT Irritability is a prevalent and impairing feature associated with autism, yet remains poorly understood, particularly in adults. Drawing heavily on insights translated from pediatric and transdiagnostic literatures, we propose that irritability in autistic individuals often reflects a psychophysiological stress or threat response, rooted in a ...
Hsiang‐Yuan Lin, Arthur N. Westover, Amy S. F. Lutz, Manish K. Jha   +3 more
wiley   +1 more source

Letter to the Editor: Cariprazine pharmacokinetics [PDF]

Australian Prescriber, 2022
Carole Ramsay, Australian Prescriber Editorial Executive Committee   +1 more
openaire   +3 more sources

Electrochemical Hofmann Rearrangement for Modular Synthesis of Unsymmetrical Ureas and Late‐Stage Modification of Drugs

Advanced Science, Volume 13, Issue 31, 4 June 2026.
An electrochemical Hofmann rearrangement of amide involving amine or other amide nucleophiles has been developed. The use of NaI guarantees the feasibility and compatibility of the electrosynthesis protocol, which enables highly chemoselective synthesis of unsymmetrical N‐acylureas from two different amides, as well as the production of unsymmetrical ...
Xue‐Qing Mou, Xiao Zha, Yu‐Rui Jian, Shao‐Xing Zhong, Xin‐Yu Fu, Sheng‐Yang Xu, Wei Xiang, Bao‐Dong Cui, Yun Zhang, Yong‐Zheng Chen   +9 more
wiley   +1 more source

Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy [PDF]

, 2013
Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist in late-stage clinical development for the treatment of schizophrenia, as well as for bipolar disorder (manic/mixed and depressive episodes), and as an adjunctive agent for the ...
Citrome, Leslie, Leslie Citrome
core   +1 more source

Characterizing treatment initiation with central nervous system–active polypharmacy among adults with dementia

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Central nervous system (CNS) –active polypharmacy, defined as concurrent use of antidepressants, antipsychotics, anti‐seizure medications, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, opioids, or skeletal muscle relaxants for ≥ 31 consecutive days, poses significant risks patients with dementia.
Donovan T. Maust, Rachel C. Davis, Julie Strominger, Steven C. Marcus, Hyungjin Myra Kim, Tanner Caverly, Frederic C. Blow, Lauren P. Wallner, Sarah Krein, Sarah E. Vordenberg   +9 more
wiley   +1 more source

From Antipsychotic to Antitumor Agent: Cariprazine Suppresses Glioblastoma via D2/D3-ARRB2 Axis Modulation

Pharmaceuticals
Background: Glioblastoma (GBM) is among the malignant tumors with the lowest five-year survival rate. Current treatments offer limited efficacy and first-line options are scarce, highlighting the urgent need for novel drugs.
Haotian Zhang, Haowei Liu, Jiangpeng Xu, Xiaoling Li, Shasha Li, Xuemei Liu, Changhua Hu   +6 more
doaj   +1 more source

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

BMC Psychiatry, 2021
Background While clinical trial evidence has firmly established the efficacy of several atypical antipsychotics (AAPs) for treating bipolar depression, no randomized controlled trials (RCT’s) comparing AAPs have been conducted. This Bayesian network meta-
Aditi Kadakia, Carole Dembek, Vincent Heller, Rajpal Singh, Jennifer Uyei, Katsuhiko Hagi, Tadashi Nosaka, Antony Loebel   +7 more
doaj   +1 more source